This Is Why Investors Will Need to Learn a New Acronym: CRISPR
In this Market Foolery segment, host Chris Hill and Motley Fool Rule Breakers' Aaron Bush talk about where genetic engineering is heading -- which is out of the lab and toward really curing diseases. Yes, it's early days. But the potential for CRISPR could be enormous. But there are some interesting speedbumps involved for biotech investors.
A full transcript follows the video.
Source: Fool.com
